This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
EARNEST was a phase 3 randomized parallel-group treatment trial evaluating second-line HIV treatment strategies.
| Feature | EARNEST |
|---|---|
| NCT ID | NCT00988039 |
| Title | Europe-Africa Research Network for Evaluation of Second-line Therapy |
| Phase | Phase 3 |
| Status | Completed |
| Start date | 2010-03 |
| Primary completion date | 2014-01 |
| Condition | Human Immunodeficiency Virus; HIV |
| Allocation | Randomized |
| Masking | None |
| Primary purpose | Treatment |
2. Clinical Question
Population
People with HIV enrolled in a phase 3 second-line therapy study.
Interventions
Aluvia + 2NRTIs; Aluvia + raltegravir; Aluvia monotherapy.
Comparator
The three randomized treatment strategies were compared within the parallel trial design.
Primary question
Which randomized second-line strategy achieves good HIV disease control at week 96?
3. Trial Design
Randomization
Participants were assigned randomly.
Design model
Parallel-group design.
Number of arms
Three intervention groups.
Masking
No masking was reported.
Study interventions
- Aluvia + 2NRTIs
- Aluvia + raltegravir
- Aluvia monotherapy
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Good HIV disease control | Composite endpoint consisting of all of: no new WHO stage 4 events; CD4 count >250 cells/mm3; viral load <10,000 copies/ml or >10,000 copies/ml with no PI resistance mutations | Week 96 |
5. Planned Analysis
The registry identifies the primary endpoint as a composite measure of HIV disease control at week 96. No statistical analyses were posted to ClinicalTrials.gov.
For a randomized trial with a binary composite endpoint, the analysis would typically compare the proportion of participants meeting the complete endpoint definition between treatment groups using an appropriate comparative statistical test and estimate uncertainty around treatment differences.
Because the endpoint requires all components to be satisfied simultaneously, interpretation depends on the definition of each component and how missing assessments are handled.
6. Statistical Methodology
Composite endpoints
The primary outcome combines multiple clinical and laboratory criteria into a single measure. Composite endpoints can increase efficiency by capturing several clinically relevant outcomes, but they require careful interpretation because failure of any component prevents meeting the overall endpoint.
Composite success = Component 1 AND Component 2 AND Component 3
A participant contributes as a success only when every required condition is satisfied.
Randomized comparisons
Randomization is intended to create comparable groups at baseline. The treatment groups can then be compared with reduced concern that observed differences are caused by measured or unmeasured baseline factors.
Missing data considerations
Composite outcomes measured over time require decisions about participants with incomplete follow-up. The registry does not report the missing-data approach used for the primary endpoint.
7. Statistical Methods Explained
Why use a composite endpoint?
A composite endpoint combines several outcomes into one measure. This can capture broader disease control, but the meaning depends on whether each component reflects an important clinical outcome.
Why does the definition require all components?
Because the endpoint is defined as consisting of all listed criteria, partial achievement does not satisfy the composite definition.
Why does randomization matter?
Randomization provides the framework for comparing intervention groups while preserving the benefits of an experimental design.
Why are time frames important?
A treatment effect measured at week 96 answers a specific question about disease control at that point in follow-up.
Why can composite endpoints be difficult to interpret?
A difference in the composite can result from differences in any component, so interpretation requires understanding the individual elements.
8. Limitations
- The ClinicalTrials.gov record does not report statistical analysis results for the primary endpoint.
- The registry does not report component-level results for the composite endpoint.
- The registry does not report subgroup analyses, safety results by arm, or missing-data methods.
- The effect of each intervention component cannot be separated from the combined randomized comparison.
9. Why This Trial Matters Statistically
| Concept | Application in EARNEST |
|---|---|
| Randomization | Three-arm randomized treatment comparison |
| Parallel design | Participants remain assigned to separate treatment groups |
| Composite endpoint | Good HIV disease control defined by multiple criteria |
| Time-based assessment | Primary endpoint evaluated at week 96 |
| Clinical interpretation | Requires understanding both the composite definition and treatment comparison |